What Is PQI, and Why Does It Matter?

If you work in pharma or biotech, you've probably seen the letters PQI attached to a deviation before you've fully unpacked what they mean. PQI stands for Product Quality Impact, and it's one of the first questions any investigation in a regulated manufacturing environment has to answer: did this deviation affect the quality of the product?

That question sounds simple. It isn't. Answering it well is one of the most consequential things an investigation does, because the answer determines how far the investigation needs to reach, and sometimes whether product already in the hands of patients or customers needs a second look.

What PQI Is Actually Asking

A PQI assessment evaluates a deviation against a standard framework often shortened to SISPQ: Safety, Identity, Strength, Purity, and Quality. Each of those terms carries a specific meaning in a regulated environment.

Safety asks whether the product could cause harm beyond its intended risk profile. Identity asks whether the product is actually what its label claims it is. Strength asks whether the active ingredient is present at the correct amount. Purity asks whether the product contains unacceptable contaminants or degradation. Quality captures the broader physical and performance attributes, things like appearance, dissolution, and stability, that patients and regulators expect to be consistent batch after batch.

A thorough PQI assessment walks through each of these deliberately. Skipping straight to "this probably doesn't affect the product" without working through the framework is how real impacts get missed.

Why This Isn't Just a Documentation Step

It's tempting to treat PQI as a box to check on the way to closing a deviation record. That instinct is understandable and also risky. The PQI assessment is often the moment an investigation decides its own scope.

If the assessment concludes there's no product quality impact, the investigation can often stay narrower: understand the deviation, identify contributing factors, close the record. If the assessment finds a real or possible impact, the investigation has to widen. That might mean pulling in additional batches, extending the review to related lots, or evaluating whether the same condition could have affected other products manufactured under similar circumstances.

Getting this wrong in either direction causes problems. Concluding "no impact" too quickly leaves a real quality issue unaddressed. Concluding "impact" too broadly without evidence can trigger investigations and holds that consume enormous resources without a clear justification. The assessment deserves the same rigor as the rest of the investigation, not less.

Two Different Questions Hiding Inside One Assessment

PQI actually asks about two different populations of product, and it's worth separating them clearly.

The first is product still within your control: material on the floor, in quarantine, or awaiting release. This is usually the more contained question. You can inspect it, retest it, hold it, and make a release decision based on what the investigation finds.

The second is product that may already be on the market, in a distribution channel, or in a patient's hands. This is a fundamentally different kind of question, because you can't simply go get it back and look at it. It requires reasoning from what you know about the deviation to what's plausible about product that already shipped, and it's where the stakes of getting the PQI assessment right go up considerably. A conclusion here can be the difference between routine documentation and a field alert or a product recall.

Why This Belongs Early, Not Late

Most companies require an initial PQI assessment within 24-48 hours of notification, based on whatever facts are known at that point. That timeline is standard industry practice reflected in most company SOPs, not a single explicit FDA regulation, but it exists for a real reason: the sooner an investigation reasons through Safety, Identity, Strength, Purity, and Quality, the sooner it can act on what it finds.

That initial assessment isn't the final word. It gets updated as the investigation develops and new facts come in, and it should. Treating the first PQI answer as fixed, rather than revisiting it as understanding deepens, is how a real quality issue can sit unaddressed longer than it should. Postponing that first look, or letting it wait until the report is otherwise finished, means the people best positioned to catch a problem early are the ones least likely to.

The question "does this affect product quality" deserves the same discipline as every other part of the investigation: work from evidence, walk the full framework, and be willing to revise the answer as you learn more. It's a small number of letters carrying a lot of weight, and it earns the time it takes to get right, starting on day one.

--

PQI and product quality assessment are covered in depth in the Investigator Foundations Certificate. Learn more about IFC.